MedTrace Logo

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

NCT06021054 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2025-10-23

No results posted yet for this study

Summary

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).

Conditions

  • Thyroid Eye Disease

Interventions

DRUG

Veligrotug (VRDN-001)

Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor

DRUG

Placebo

5 IV infusions of placebo

Sponsors & Collaborators

  • Viridian Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-14
Primary Completion
2024-11-04
Completion
2025-07-25
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Germany
  • Hungary
  • Poland
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06021054 on ClinicalTrials.gov